Emerging from gastroesophageal reflux (EMERGE): an Italian survey - I the viewpoint of the gastroenterologist.

Autor:	Bianchetti M; Gastroenterologia - Humanitas Mater Domini, Castellanza (VA), Italy, Peralta S; Endoscopia Digestiva – Policlinico P. Giaccone, Università di Palermo, Palermo, Italy, Nicita R; Gastroenterologia - ASP 5, Reggio Calabria, Italy, Aragona SE; Center of Regenerative Medicine - Humanitas Mater Domini, Castellanza (VA), Italy, Ciprandi G; Center of Regenerative Medicine - Humanitas Mater Domini, Castellanza (VA), Italy
Jazyk:	angličtina
Zdroj:	Journal of biological regulators and homeostatic agents [J Biol Regul Homeost Agents] 2018 Jul-Aug; Vol. 32 (4), pp. 973-981.
Abstrakt:	Gastroesophageal reflux disease (GERD) is defined as a “disease that develops when the reflux of stomach contents induces troublesome symptoms and/or complications”. From a therapeutic point of view, many options have been proposed, including proton pump inhibitors (PPI), antihistamines (H2- receptor antagonists), antacid chemical compounds, antireflux barrier (using alginates), prokinetics, inhibitors of gastric sphincters, protection of mucosal tissue, neuromodulators, nociceptor antagonists, lifestyle modification, and surgery. A new medical compound has been recently launched in Italy: Marial® (manufactured by Aurora, Milan, Italy) containing magnesium alginate and E-Gastryal®. The aim of this survey was to analyse the patients’ characteristics and the prescriptive approach considering both the past or current treatments and clinical features during a visit in 56 gastroenterological centers, distributed in the whole of Italy. One thousand eight hundred forty-nine patients (46.5% males, and 53.5% females, mean age 48.59 years) were visited. Patients with positive reflux symptoms index (RSI+) had higher GIS scores than RSI- subjects. PPIs (both as monotherapy or plus add-on) were the most common medication prescribed before the visit. There was a significant change of prescription to Marial® at the visit. More precisely,, Marial® was preferentially prescribed to about a quarter of the patients, particularly to those with lower GIS score, whereas PPI plus add-on option was preferred for patients with higher GIS score. In conclusion, the current experience demonstrated that GERD may be managed considering a patient-centred work-up by using the GIS questionnaire. GIS score may be able to define the medication choice that includes also the new medical compound Marial®. (Copyright © by BIOLIFE, s.a.s. This publication and/or article is for individual use only and may not be further reproduced without written permission from the copyright holder. Unauthorized reproduction may result in financial and other penalties)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu